Volume 16 Supplement 1
Abstracts from the 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications
Meeting abstracts
Edited by Johannes-Peter Stasch, John Burnett, Harald Schmidt, Michaela Kuhn and Franz Hofmann
Publication of this supplement has been fully funded by FEBGLA e.V. Johannes-Peter Stasch is an employee of Bayer Pharma AG, Wuppertal, Germany. He holds many patents on sGC stimulators and sGC activators. John C Burnett Jr is the chairman of the advisory board for Nile Therapeutics and is a Co-Founder and the Chief Scientific Officer for Zumbro Discovery. Mayo Clinic has licensed CD-NP to Nile Therapeutics and MANP to Zumbro Discovery. The other Supplement Editors declare that they have no competing interests.
7th International Conference on cGMP Generators, Effectors and Therapeutic Implications. Go to conference site.
Trier, Germany19-21 June 2015
Page 2 of 3
-
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A51
-
Modulation of cGMP/cAMP crosstalk on the level of PDE3 in animals lacking NO-sensitive guanylyl cyclase
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A52 -
Erythrocytes do not produce biologically active NO
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A53 -
Concomitant administration of sGC stimulators with common classes of anti-hypertensive agents results in increased efficacy in spontaneously hypertensive rats
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A54 -
NO-dependent cGMP signalling in neurons and astrocytes
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A55 -
Cell-specific modulation of gastrointestinal NO-induced relaxation by phosphodiesterases
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A56 -
The sGC stimulator BAY 41-8543 in a rat model of hypertension-induced heart failure
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A57 -
The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A58 -
Discovery of IWP-051, a Novel Orally Bioavailable Soluble Guanylate Cyclase Stimulator with Sustained and Dose-Dependent Hemodynamic Effects
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A59 -
Cyclic GMP Dependent Protein Kinase (PKG) as a mediator of EGFR-Induced Apoptosis in Breast Cancer
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A60 -
CNP attenuates renal toxicity induced by cisplatin in murine kidney
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A61 -
The NO-cGMP pathway participates in vascular adaptation to oxidative stress in Nrf2 KO mice
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A62 -
Correlation of vascular smooth muscle cell phenotype and cGMP signalling
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A63 -
Rational design of a PKA-based sensor for cGMP
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A64 -
Nitrite is a cGMP generator in isolated platelets
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A65 -
Enhancement of cAMP-mediated inotropic responses by CNP is regulated differently by PDE2 in normal and failing hearts
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A66 -
Contribution of the NO-GC isoforms to airway responsiveness
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A67 -
Comparative analysis of established and new biosensors for cyclic nucleotides
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A68 -
Differential role of NO-sensitive guanylyl cyclase isoforms NO-GC1 and NO-GC2 in auditory function in adult mice
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A69 -
Identification and characterization of small molecular NPR-B receptor antagonists
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A70 -
Natriuretic peptides regulate sympathetic nervous activity independent of mineralocorticoid receptor
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A71 -
The world's first clinical randomized trial of atrial natriuretic peptide for preventing cancer recurrence following lung cancer surgery
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A72 -
NMR study of a soluble Guanylate Cyclase (sGC) human homologue: the H-NOX domain from Nostoc sp.
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A73 -
Functions of NO-GC1 and NO-GC2 in pain processing
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A74 -
Tadalafil protects from doxorubicin-induced heart failure by attenuating PKG Iα disulfide dimerisation
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A75 -
Asymmetric properties of rod cGMP Phosphodiesterase 6 (PDE6): structural and functional analysis
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A76 -
Riociguat and cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A77 -
C-type natriuretic peptide prevents angiotensin II-induced cardiac remodelling and dysfunction
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A78 -
Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A79 -
Evaluating a possible role for PKG1α redox state in chronic hypoxia-induced pulmonary hypertension
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A80 -
Age, noise and cGMP: Pharmacological activation of soluble guanylyl cyclase (sGC) interacts with the progression of age related and noise induced hearing loss
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A81 -
Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A82 -
Effects of obesity on sGCβ1 mediated signaling in white adipose tissue
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A83 -
Differentiation between first and second messenger effects of cGMP
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A84 -
cIMP: Synthesis, effector activation, inactivation and occurrence in biological systems
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A85 -
IWP-121: a novel sGC stimulator that reduces blood pressure and exhibits anti-fibrotic and anti-inflammatory activities in the Dahl Salt-Sensitive rat model
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A86 -
Snake venom natriuretic peptides: Potential molecular probes
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A87 -
The effect of natriuretic peptides and bradykinin on development of brain oedema after ischemic stroke
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A88 -
Natriuretic peptides, via GC-A/cGMP, moderate hypoxia-induced VEGF release from astrocytes and thereby pathological neovascularization in the retina
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A89 -
Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A90 -
Direct visualization of cGMP microdomains in adult cardiomyocytes
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A91 -
Role of atrial natriuretic peptide (ANP) in the regulation of insulin secretion and vitality of pancreatic ß cells
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A92 -
Influence of smoking on vascular reactivity to cGMP generators in human internal thoracic arteries
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A93 -
Linaclotide-induced electrolyte secretion in human and rat colon: Ussing chamber studies
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A94 -
Identification of new inhibitors of soluble guanylyl cyclase activity
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A95 -
Cardiac soluble guanylate cyclase protects against the cardiac dysfunction induced by chronic doxorubicin treatment in mice
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A96 -
Androgen-sensitive hypertension associated with soluble guanylate cyclase alpha1 deficiency is mediated by 20-HETE
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A97 -
Real-time imaging of cGMP signals in platelets
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A98 -
Differences in the renal antifibrotic signaling of serelaxin and zaprinast
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A99 -
Functional evaluation of GUCY1A3 mutations associated with myocardial infarction risk
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A100
Annual Journal Metrics
-
2022 Citation Impact
2.9 - 2-year Impact Factor
2.9 - 5-year Impact Factor
0.932 - SNIP (Source Normalized Impact per Paper)
0.603 - SJR (SCImago Journal Rank)2022 Speed
26 days submission to first editorial decision for all manuscripts (Median)
198 days submission to accept (Median)2022 Usage
642,939 downloads
1,154 Altmetric mentions
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication